In murine L cells, treatment with calpeptin or calpain inhibitor III increased A␤42, but not A␤40, secretion in a dose-dependent fashion. This correlated with an increase in the levels of amyloid precursor protein (APP) carboxyl-terminal fragments (CTFs). Immunoprecipitation with novel mAbs directed against the carboxyl-terminus of APP or specific for the ␤-cleaved CTF showed that generation of both ␣-and ␤-cleaved CTFs increase proportionately following inhibition of calpains. Pulsechase metabolic labeling confirmed that inhibiting calpains increases the production of ␣-and ␤-cleaved APP metabolites. Immunolabeling showed greater ␤CTF signal in calpeptin-treated cells, primarily in small vesicular compartments that were shown to be predominantly endosomal by colocalization with early endosomal antigen 1. A second mAb, which recognizes an extracellular/ luminal epitope found on both APP and ␤CTFs, gave more cell surface labeling of calpeptin-treated cells than control cells. Quantitative binding of this antibody confirmed that inhibiting calpains caused a partial redistribution of APP to the cell surface. These results demonstrate that 1) calpain inhibition results in a partial redistribution of APP to the cell surface, 2) this redistribution leads to an increase in both ␣-and ␤-cleavage without changing the ratio of ␣CTFs/␤CTFs, and 3) the bulk of the ␤CTFs in the cell are within early endosomes, confirming the importance of this compartment in APP processing.
In murine L cells, treatment with calpeptin or calpain inhibitor III increased A␤42, but not A␤40, secretion in a dose-dependent fashion. This correlated with an increase in the levels of amyloid precursor protein (APP) carboxyl-terminal fragments (CTFs). Immunoprecipitation with novel mAbs directed against the carboxyl-terminus of APP or specific for the ␤-cleaved CTF showed that generation of both ␣-and ␤-cleaved CTFs increase proportionately following inhibition of calpains. Pulsechase metabolic labeling confirmed that inhibiting calpains increases the production of ␣-and ␤-cleaved APP metabolites. Immunolabeling showed greater ␤CTF signal in calpeptin-treated cells, primarily in small vesicular compartments that were shown to be predominantly endosomal by colocalization with early endosomal antigen 1. A second mAb, which recognizes an extracellular/ luminal epitope found on both APP and ␤CTFs, gave more cell surface labeling of calpeptin-treated cells than control cells. Quantitative binding of this antibody confirmed that inhibiting calpains caused a partial redistribution of APP to the cell surface. These results demonstrate that 1) calpain inhibition results in a partial redistribution of APP to the cell surface, 2) this redistribution leads to an increase in both ␣-and ␤-cleavage without changing the ratio of ␣CTFs/␤CTFs, and 3) the bulk of the ␤CTFs in the cell are within early endosomes, confirming the importance of this compartment in APP processing.
The deposition of the small (ϳ40 -42 residues) A␤ peptide as insoluble ␤-amyloid plaque in the brain parenchyma is an invariant feature of Alzheimer's disease. A␤ is generated by proteolysis of the ϳ100-kDa amyloid precursor protein (APP), 1 a broadly expressed type 1 transmembrane protein that is found primarily in the trans-Golgi network (TGN) and at the cell surface (reviewed in Ref. 1) . The ␤-cleavage of APP occurs within the luminal/extracellular domain of APP and generates two APP fragments: a large, soluble amino-terminal fragment (sAPP␤) that is secreted from the cell and a transmembrane, carboxyl-terminal fragment (CTF) that remains associated with the cell. This ␤CTF consists of 99 amino acids, contains the whole A␤ peptide, and has a molecular mass of ϳ10 kDa. An alternative pathway involves the cleavage of APP 16 residues downstream of this site at the ␣-cleavage site. Like ␤-cleavage, ␣-cleavage generates a sAPP fragment (sAPP␣) that is secreted from the cell and an ␣CTF (of 84 residues and ϳ8 kDa) that remains membrane-associated. ␣-Cleavage occurs within the A␤ peptide sequence and as such prevents the generation of A␤ from a given APP molecule. A␤ is generated from the ␤CTF by an intramembrane cleavage (␥-cleavage) that occurs primarily at 40 residues, and to a lesser extent 42 residues, downstream from the ␤-cleavage site, releasing A␤1-40 or A␤1-42.
Much progress has been made recently in identifying the major proteases/protease complexes responsible for ␣-, ␤-, and ␥-cleavage (the ␣-, ␤-, and ␥-secretases). ␣-Cleavage appears to be due to the activity of two metalloproteases (TACE and ADAM10) and is thought to occur primarily at the cell surface (2-7). The BACE proteases, a recently identified family of transmembrane apartyl proteases, appear to account for much of the ␤-secretase activity within normal cells (8, 9) . BACE has an endosomal-lysosomal pattern of distribution as well as an acidic pH optimum (9 -11); BACE-mediated cleavage of APP in the endocytic system is consistent with prior work that has identified, through various trafficking mutants of APP, the early endosome as an important site for A␤ generation (12) (13) (14) and as a compartment showing functional alterations at the earliest stages of AD (15) . The presenilin (PS) proteins play an intimate role in ␥-cleavage; expression of familial AD-causing mutant presenilin increases the production of A␤ terminating at residue 42 (16 -18) , the PS-null phenotype includes the inability of the cell to generate A␤ and the intracellular accumulation of CTFs (19, 20) , and recent work has directly implicated PS itself as the ␥-secretase (21), although other proteins within the PS complex such as nicastrin (22) may well be directly involved in ␥-cleavage.
The calpain system consists of two Ca 2ϩ -activated, cytosolic, neutral pH, cysteine proteases, which are typically distinguished by their different affinities for Ca 2ϩ in vitro (m-calpain and -calpain), as well as an endogenous inhibitor, calpastatin (23) (24) (25) . Calpains play a central role in cytoskeleton remodel-ing (26) , have been suggested to play a regulatory role in some vesicular transport events (27) , and are the primary mediators of cell death following an unregulated increase in intracellular Ca 2ϩ concentration, as occurs with excitotoxicity (28, 29) . The calpain system appears to be up-regulated during AD, with evidence that both m-calpain and -calpain are abnormally activated in neurons (30 -32) . These changes in the calpain system are most often thought to impact tau metabolism, due in part to their known roles in tau turnover (33, 34) and regulation of kinases thought to be involved in tau hyperphosphorylation and proteolysis (32, 33, 35) .
Calpain activity may also modulate A␤ production. Inhibiting calpain activity increases A␤ production by cells in culture, with A␤42 increasing more than A␤40 (36 -39) . In addition, calpain inhibitors have been shown to increase the levels of CTFs in cells (39, 40) . Zhang et al. (39) examined this effect in cells overexpressing an APP ␤CTF construct and concluded that the increase in CTFs was due to their stabilization, but the mechanism(s) underlying such an increase in CTFs derived from APP holoprotein has yet to be examined in detail.
To this end, we have examined the metabolism and intracellular distribution of APP in cells following treatment with calpain inhibitors. Our results confirm that calpain inhibitors greatly increase A␤42 generation, while having a smaller effect on A␤40. We found that inhibiting calpains resulted in a substantial and proportionate increase in the generation of both ␣-and ␤-cleaved CTFs and that this increase in the production of CTFs is likely to be the result of a partial redistribution of APP from the TGN to the plasma membrane. Using a monoclonal antibody that specifically recognizes the ␤CTF, we show that ␤CTFs colocalize with a marker of the early endosome, both without treatment and following calpain inhibitor treatment. These data suggest a model in which inhibiting the calpain system drives a greater proportion of APP to the cell surface and early endosomes, where ␣-cleavage and ␤-cleavage, respectively, can then occur. The additional ␤CTFs generated are then substrate for ␥-42-secretase activity, further linking the generation of this highly pathogenic species of A␤ to the early endosome.
MATERIALS AND METHODS
Cell Lines, cDNA Constructs, and Transfections-Ltk cells (a murine fibroblast-like cell line (41) ) were maintained at 37°C and 5% CO 2 in high glucose Dulbecco's modified Eagle's medium (Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum (Invitrogen), 2 mM glutamax I (Invitrogen), and penicillin/streptomycin (Cellgro). cDNAs encoding human APP 695 (42) or PS1 with the P117L mutation (43) were inserted into the mammalian expression vector pcDNA3 (Invitrogen). Following transfection using Lipofectin (manufacturer's protocol; Invitrogen), stable L cell lines were selected in 400 g/ml G418 (Invitrogen) and screened for expression (42, 44) . N2a (17) and IMR-32 (45) neuroblastomas were obtained from the American Type Culture Collection (Gaithersburg, MD) and maintained as recommended by the ATCC.
Antibodies- Table I describes the six monoclonal antibodies directed against APP and/or APP metabolites used in this study; Fig. 1 is a schematic diagram showing the use of these antibodies to detect APP metabolites. C1/6.1 was raised against the conserved carboxyl-terminal 20 residues of APP (residues 676 -695 of APP 695 ) and is useful for immunolabeling, immunoprecipitation, and Western blot analysis (42) . JRF/A␤N/25 was raised against a synthetic peptide encompassing residues 1-7 of human A␤. Evidence that JRF/A␤N/25 requires ␤-cleavage at residue 1 of A␤ has been presented by Vandermeeren et al. (46) and is substantiated by this study. JRF/A␤tot/17 was raised against human A␤1-40; mapping of its epitope against synthetic peptides has demonstrated that JRF/A␤tot/17 binds within residues 1-15 and is specific for human A␤. JRF/rA␤1-15/2 was raised against a synthetic peptide encompassing residues 1-15 of murine A␤ and does not recognize human A␤ or human APP (42, 46) . JRF/cA␤40/10 was raised against the carboxyl-terminal 5 residues of A␤1-40, and JRF/cA␤42/26 was raised against the carboxyl-terminal 10 residues of A␤1-42. These A␤ carboxyl-terminal antibodies, their specificity, and their use in our sandwich ELISA has been recently described (42, 47 (49, 50) . Sandwich ELISAs-Sandwich ELISAs using these antibodies were done essentially as previously reported (42, 47, 51) , with modifications to detect either human or murine A␤ secreted into the growth media. Nunc-Immuno Plates (Nunc A/S, Roskilde, Denmark) were coated overnight at 4°C using a 10 g/ml concentration of either JRF/cA␤40/10 in 10 mM Tris, 10 mM NaCl, pH 8.5, or JRF/cA␤42/26 in 100 mM bicarbonate buffer, pH 9.6, and the remaining protein binding sites were blocked by incubating with 1% Block Ace (Dainippon Pharmaceutical, Osaka, Japan) in PBS for 4 h at room temperature. Cells were seeded onto six-well dishes and allowed to settle overnight. Human APP or PS1 P117L expression in L cells was induced with 20 mM butyrate for ϳ40 h (41), whereas neuroblastoma lines were allowed to grow to near confluence. Growth medium was then replaced with 0.8 ml of fresh medium containing calpeptin or calpain inhibitor III (Calbiochem) and, for transfected L cells, butyrate. After 6 h, this conditioned medium was collected and HEPES (pH 7.4) was added to 25 mM and loaded undiluted into duplicate wells for ELISA. Human and murine A␤1-40 and A␤1-42 peptide standards were purchased from American Peptide Co. (Sunnyvale, CA); stock solutions were stored at Ϫ70°C and further diluted immediately prior to use. ELISA plates were incubated overnight at 4°C with samples and standards. A␤ was detected by incubating for 4 h at room temperature with horseradish peroxidase-conjugated JRF/A␤tot/17 (human A␤) or JRF/rA␤1-15/2 (murine A␤) diluted in 20 mM sodium phosphate, 2 mM EDTA, 400 mM NaCl, 1% bovine serum albumin, pH 7.0. ELISA plates were developed using a color reaction (TMB Microwell Peroxidase Substrate System, Kirkegaard & Perry, Gaithersburg, MD), and the A 450 was read. ELISA signals are reported as the mean Ϯ S.E. of two or more wells in fmol of A␤/ml of medium.
Metabolic Labeling, Immunoprecipitation, and Western Blot Analysis-To detect APP and CTFs, 5 ϫ 10 5 cells were seeded onto 35-mm diameter tissue culture dishes followed by induction with 20 mM butyrate for 24 h (41). Cultures were methionine/cysteine-starved for 20 min, pulse-labeled for 15 min with 100 Ci/ml Tran 35 S-label (PerkinElmer Life Sciences), washed, and chased in complete medium containing 2 mM unlabeled methionine (41) . Calpain inhibitors, as described under ''Results,'' were added to the growth media 3 h prior to methionine/ cysteine starvation and then throughout pulse labeling and chase. Cell lysates (prepared in 1% Triton X-100, 140 mM NaC1, 25 mM Tris, pH 7.4, 0.5 mM EDTA, 10 mM methionine, and protease inhibitors (41, 52) ) were subjected to immunoprecipitation with one of several monoclonal antibodies as described under ''Results.'' Sequential immunoprecipitation of the growth medium to isolate metabolically labeled sAPP␣ and sAPP␤ has been described (42) . Immunoprecipitated proteins were sized by SDS-PAGE, and labeled proteins visualized by exposure to x-ray film and analyzed quantitatively using a Storm 840 PhosphorImager (Amersham Biosciences) and/or by scan analysis (NIH Image).
For Western blot analysis, protein concentration in cell lysates was determined (Bio-Rad DC Protein Assay), and equal amounts of proteins were separated by SDS-PAGE gels and transferred to polyvinylidene difluoride membrane. Membranes were incubated in C1/6.1 (2 g/ml) overnight, washed, and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG for 1.5 h. Membranes were washed, and ECL substrate (Amersham Biosciences) was added before exposure to x-ray film.
Quantitative 125 I-mAb Binding-Sodium [ 125 I]iodide was purchased from PerkinElmer Life Sciences. Monoclonal antibodies JRF/A␤tot/17 and JRF/A␤N/25 were iodinated using iodogen tubes (Pierce; manufacturer's protocol), and 125 I-mAb was recovered (41) . APP-overexpressing L cells grown in six-well dishes were butyrate-induced for ϳ40 h as described above, fixed at room temperature (as for immunolabeling) and incubated for 2 h with 10 6 cpm 125 I-mAb (adjusted to 2 g/ml total mAb with unlabeled mAb) in Hanks' balanced salt solution, 10% horse serum, 20 mM HEPES (pH 7.4) as previously described (41) . Following washes, bound 125 I-mAb was recovered in 2 ml of 1 N NaOH and counted in a ␥ counter. 0.1% saponin (w/v; Sigma) was added to the binding solution to permeabilize cells. Nonspecific binding was estimated using identical cultures of nontransfected L cells and a 50-fold excess of unlabeled mAb in the binding solution; all data points represent nonspecific binding subtracted from specific binding, each the mean of triplicate measurements Ϯ S.E.
Immunolabeling-For indirect immunofluorescence labeling, L cells were seeded onto glass coverslips, and expression of APP was induced. Cells were fixed in 4% paraformaldehyde, 5% sucrose in PBS (pH 7.4) at room temperature for 15 min and immunolabeled as previously described (41) . Fluorescein-and Texas Red-coupled secondary antibodies were purchased from Cappel (Durham, NC). Cells were permeabilized by the addition of 0.1% saponin to the antibody-containing solutions. Cells were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and examined by epifluorescence and laser confocal microscopy.
RESULTS

Calpain Inhibitors Increase A␤42 Secretion Selectively While
Increasing CTF Levels-Initially, we sought to confirm previous findings (36 -38) , which have showed that inhibition of calpains predominantly affected A␤ by increasing A␤42 production, using a murine fibroblast-like line (L cells) as well as murine and human neuroblastoma lines (Table II) . By sandwich ELISA, we determined the amount of A␤40 and A␤42 secreted into the growth media over a 6-h period by control cells or by cells treated with the calpain inhibitor calpeptin. In L cells, calpeptin treatment consistently increased the amount of secreted A␤42, typically 2-3-fold over that secreted by control cells, while increasing A␤40 secretion less than 1.5-fold. In an L cell line expressing an FAD mutant PS1 (L/PS1 P117L ) (43), again we found that A␤42 increased more than A␤40, although the initial levels of A␤42 were higher due to expression of the mutant PS1 (see Fig. 2 ). When we examined A␤ secretion in an L cell line expressing human APP 695 (L/APP) (42) using an ELISA specific for human A␤, we obtained similar results, with A␤40 essentially unchanged and A␤42 again increased 3.5-fold by calpeptin treatment. Similar increases with calpeptin treatment were also seen in the murine neuroblastoma cell line N2a and the human hippocampal neuroblastoma line IMR-32 (45) , with A␤42 increasing ϳ3-fold and A␤40 remaining nearly unchanged. These data emphasize that calpain inhibition with calpeptin has a much greater effect on A␤42 than on A␤40 and, importantly, that this effect is seen in nonneuronal as well as neuron-like cells.
Previous reports have shown that, in addition to increasing A␤42 production, inhibiting calpains increases the steady-state level of APP CTFs detected within cells (39, 40) . In the experiment shown in Fig. 2 , we examined the interrelationship between A␤ production and the steady-state CTF levels following calpain inhibition in L cells. Fig. 2A shows ELISA data for A␤ generated from the endogenous murine APP in L cells and in L cells expressing a mutant presenilin 1 (PS1 P117L ) (43) at increasing concentrations of calpain inhibitor III. A␤40 levels in the parental and the PS1 P117L -expressing L cells were found to be similar and did not increase significantly with calpain inhibitor III at any concentration. Base-line A␤42 production was greater in the mutant PS1-expressing L cells. 5-25 M calpain inhibitor III treatment resulted in a nearly parallel increase in A␤42 produced by either the control or PS1 P117L -expressing L cells. Both A␤40 and A␤42 levels were found to dramatically decrease to below detectability at the highest calpain inhibitor III concentrations (100 and 250 M). Additional experiments, including pulse-metabolic labeling and immunoprecipitation of APP, demonstrated that this was the result of calpain inhibitor III blocking protein biosynthesis at these high concentrations (data not shown). This is consistent with the observations of Zhang et al. (39) that high concentrations of calpain inhibitors decreased both A␤40 and A␤42 generation and may explain an apparent decrease in CTF degradation at these toxic concentrations. We initially examined the relationship between CTF levels and calpain inhibition by Western blot analysis using the monoclonal antibody C1/6.1 (42) , which was raised against the carboxyl-terminal 20 amino acids of APP and recognizes the holoprotein as well as multiple CTFs (Fig. 2B) . Quantitation of this Western blot demonstrates a substantial increase in CTF levels with increasing calpain inhibitor III concentrations. At the highest concentration, however, both APP holoprotein, and to a lesser extent, CTFs decline precipitously, which is consistent with these high doses of the inhibitor blocking protein biosynthesis. These results demonstrate that CTF levels and A␤42 production following calpain inhibition correlate strongly.
Calpain Inhibitors Increase the Generation of Both ␣-and ␤-Cleaved APP Metabolites-To determine what species of CTFs were appearing following calpain inhibitor treatment, we immunoprecipitated APP holoprotein and CTFs using a set of monoclonal antibodies that recognize different epitopes within the carboxyl-terminal 99 residues of APP (see Table I ). In addition to the monoclonal antibody C1/6.1, we used two monoclonal antibodies raised against A␤ epitopes: JRF/A␤N/25, which was raised against a peptide consisting of the aminoterminal 7 residues of A␤, and JRF/A␤tot/17, which was raised against A␤1-40 and has been shown by peptide-epitope mapping to recognize a sequence contained within residues 1-16 of human A␤. In the experiment shown in Fig. 3 , L cells overexpressing human APP 695 (L/APP cells) were metabolically labeled for 15 min followed by a chase for 1 h. Cells were treated for 3 h prior to as well as during the pulse and chase periods with the indicated calpain inhibitors. Equal volumes of detergent lysates prepared from the pulse and chase periods were subjected to immunoprecipitation with each monoclonal antibody, and labeled APP species were resolved by 4 -20% gradient SDS-PAGE. In untreated L/APP cells (Fig. 3, lanes 1-6) , C1/6.1 immunoprecipitated labeled holoprotein from the pulse period (lane 1). Following a 1-h chase, C1/6.1 immunoprecipitation also revealed two rapidly migrating APP fragments that migrated at ϳ10 and 8 kDa, consistent in size with the ␣CTF and ␤CTF (Fig. 3, 3 and 6, respectively) , as well as the ␤CTF following chase. Given the specificities of these three monoclonal antibodies and the mobility on SDS-PAGE of the CTFs they immunoprecipitate, we conclude that the most rapidly migrating species identified by C1/6.1 is the ␣-cleaved CTF.
In cells treated with either 10 M calpeptin or 10 M calpain inhibitor III, the immunoprecipitation pattern from the pulselabeled lysates was similar to that seen from untreated cells (compare lanes 1-3 with lanes 7-9 and 13-15) , although calpain inhibitor III treatment increased the relative signal from a number of bands detected by C1/6.1 and JRF/A␤tot/17 that migrated more rapidly than APP holoprotein but more slowly than the CTFs. With calpain inhibition, striking differences in the abundance of CTFs, however, were seen following a 1-h chase. C1/6.1 immunoprecipitation demonstrated a substantial and apparently proportionate increase in the levels of both ␣CTFs and ␤CTFs with either calpain inhibitor (compare lane 4 with lanes 10 and 16). This increase in the ␤CTF was confirmed by immunoprecipitation with JRF/A␤N/25 and JRF/ A␤tot/17 ( lanes 11, 12, 17, and 18) . Densitometric quantitation of these bands from the C1/6.1 immunoprecipitation confirmed our observation that the ratio of ␣CTF to ␤CTF appears not to be affected by calpain inhibition (remaining at ϳ2:1) despite an approximate 4-fold increase in both CTFs. Finally, it should be noted that the APP holoprotein contains 5 times more methionines than do the CTFs, so that metabolic labeling substantially underestimates the relative abundance of the CTFs.
The 1-h chase shown in Fig. 3 suggests that calpain inhibition increases the production of CTFs, although a slowing of their turnover might have the same effect. We directly addressed the generation and turnover of the CTFs as well as the production of sAPP in the pulse-chase experiment shown in Figs. 4 and 5. In Fig. 4 , L/APP cells were pulse-labeled for 15 min and chased for the indicated times up to 6 h prior to immunoprecipitation of lysates with C1/6.1. In Fig. 4A , the top panel shows that the turnover of APP holoprotein in control (lanes 1-6) and 10 M calpeptin-treated cells (lanes 7-12) is similar. The bottom panel shows a longer exposure of the same immunoprecipitation showing the generation and turnover of the CTFs. In agreement with the data in Fig. 3 , 10 M calpeptin treatment substantially increased the generation of both ␣ and ␤ CTFs during the initial 1 h of chase (compare lanes 1-3 with  lanes 7-9) ; in contrast to a previous interpretation (39), however, this calpeptin concentration did not appear to reduce the turnover of CTFs. Quantitation of these data confirmed that the turnover of APP holoprotein is unchanged by calpeptin treatment (Fig. 4B) . Additionally, the rate of CTF degradation, like the turnover of APP, does not appear to be affected by calpeptin treatment. These findings also support the hypothesis that the increase in A␤42 seen following calpain inhibition is due to increased production of ␤CTFs. Indeed, with calpeptin treatment and at 1-h chase, the combined ␣CTF and ␤CTF signal accounts for ϳ40% of the metabolically labeled APP present in the pulse period, indicating the importance of these metabolic pathways following calpain inhibition.
In order to demonstrate that calpain inhibition promotes the ␣-and ␤-cleavage of APP, we immunoprecipitated sAPP␣ and sAPP␤ from the growth media of untreated L/APP cells (Fig. 5,  lanes 1-4) and calpeptin-treated cells (lanes 5-8) at various chase times following a 15-min pulse labeling. In general,
FIG. 3. Calpain inhibitors increase the generation of both ␣-and ␤-cleaved
CTFs. An L cell line overexpressing human APP was metabolically labeled for 15 min and chased for 1 h as indicated. Cells were pretreated with the indicated calpain inhibitors for 3 h prior to metabolic labeling as well as during labeling and chase. Cell lysates were prepared, and equal volumes were immunoprecipitated with one of three monoclonal antibodies: C1/6.1, which recognizes an epitope within the 20 carboxyl-terminal-most residues of APP; JRF/A␤N/25, which recognizes residues 1-7 of A␤; and JRF/A␤tot/17, which recognizes an epitope within residues 1-16 of A␤. Labeled, immunoprecipitated proteins were sized on SDS-PAGE and detected as described under ''Materials and Methods.'' The arrows indicate the APP holoprotein (APP fl ) and the ␣-and ␤-cleaved CTFs (␣CTF and ␤CTF, respectively).
greater levels of sAPP␣ and sAPP␤ were seen in the calpeptintreated cells when compared with the control cells. In both conditions, sAPP␣ and sAPP␤ were detectable after a 1-h chase, with their levels increasing significantly by 2 h of chase time. Whereas sAPP levels remained constant from 2-4-h chase time in the untreated cells, a small increase in both sAPP␣ and sAPP␤ levels was seen in the calpeptin-treated cells between 2 and 3 h (compare lanes 6 and 7). Since sAPP levels were found to be nearly maximal after a 2-h chase period, we performed a series of four pulse-labeling experiments in which sAPP␣ and sAPP␤ were immunoprecipitated following a 2-h chase period from untreated and 10 M calpeptin-treated cells.
Quantitation of these experiments showed a greater than 2-fold increase of both sAPP␣ and sAPP␤ levels in the media of calpeptin-treated cells versus untreated cells (sAPP␣, 2.2 Ϯ 0.8; sAPP␤, 2.4 Ϯ 0.6; mean increase of calpeptin-treated cells relative to untreated cells Ϯ S.E.). Given that both sAPP species appear to be quite stable in the growth media in both control conditions as well as following calpain inhibition, the likely explanation for an increase in sAPP␣ and sAPP␤ levels following calpeptin treatment is an increase in ␣-and ␤-cleavage of APP. This result argues that calpain inhibition results in an increase in these cleavage events and, therefore, an increase in the production of sAPP␣, sAPP␤, ␣CTF, and ␤CTF. It should ␤CTF) . B, quantitation of this pulse-chase experiment is shown, illustrating the rapid turnover of the APP holoprotein, which is unaffected by calpeptin treatment, and the dramatic and proportionate increase in ␣CTF and ␤CTF generation with calpeptin treatment.
be noted, however, that the increase in maximal CTF levels detected by pulse-chase labeling was found to be greater (ϳ4-fold; see Fig. 4 ) than the increase in sAPP levels shown above, suggesting that part of the calpain inhibitor effect may be a slowing in the turnover of the CTFs after their generation. While we cannot rule out this possibility, our pulse-chase data (Fig. 4) show that the stability of the CTFs following calpain inhibition is not extended greatly.
␤CTFs Colocalize with an Early Endosomal Marker, EEA1-That JRF/A␤N/25 specifically recognizes the ␤CTF of APP allowed us to determine the levels and intracellular distribution of this APP proteolytic fragment by immunolabeling. Fig. 6 shows the JRF/A␤N/25 labeling pattern in control L/APP cells (A-C) and L/APP cells treated for 6 h with 10 M calpeptin (D-F). JRF/A␤N/25 primarily decorated small, punctate structures distributed throughout the cell (A). Consistent with our Western blot and metabolic labeling data, the intensity of JRF/ A␤N/25 immunolabeling increased following calpeptin treatment, although the pattern of labeling was similar (Fig. 6,  compare A with D) . Given that this pattern suggests a small vesicular compartment and previous work that has suggested early endosomes as a likely site of APP proteolysis leading to A␤ generation (12, 13, 15) , we co-immunolabeled with a polyclonal antibody directed against early endosomal antigen 1 (Fig. 6, B and E) , a protein that interacts with the early endosomal membrane and associated regulatory proteins (49, 50, 53, 54) . JRF/A␤N/25-labeled ␤CTFs showed striking coincidence with EEA1, both in the control cells (C) and the calpeptin-treated cells (F). This co-immunolabeling result suggests that many of the ␤CTF within these cells are located in early endocytic compartments and that calpain inhibition does not substantially alter this distribution.
Calpain Inhibitors Cause a Partial Redistribution of APP to the Cell Surface-We performed similar immunolabeling experiments using JRF/A␤tot/17, which recognizes APP holoprotein as well as the ␤CTF, and C1/6.1, which recognizes APP holoprotein and all CTFs. Fig. 7 shows co-immunolabeling with JRF/A␤tot/17 and the EEA1 antiserum; results with C1/6.1 were similar. In control L/APP cells, JRF/A␤tot/17 showed strong perinuclear labeling, consistent with an important TGN localization for APP, as well as lesser labeling of peripheral structures (A). With calpeptin treatment, however, JRF/A␤tot/17 showed similar perinuclear labeling yet much greater labeling of the cell's periphery (E). This peripheral labeling included demarcation of the cell's surface, which we confirmed to be plasma membrane localization by demonstrating immunolabeling of nonpermeabilized cells with JRF/A␤tot/17 (Fig. 7, compare D (untreated cells), with H  (calpeptin-treated cells) ). A consistent finding by immunolabeling was greater JRF/A␤tot/17 binding at the cell surface following calpain inhibition. The EEA1 localization (Fig. 7, B and F) and the overlay of JRF/A␤tot/17 and EEA1 immunolabeling in these cells (C and G), demonstrated that, unlike the JRF/A␤N/25 immunolabeling (Fig. 6) , the majority of the APP detected by JRF/A␤tot/17 is not within early endosomes.
Whereas these results suggest a partial redistribution of APP to the cell surface following calpain inhibition, we further confirmed this finding by quantitative 125 I-mAb binding to intact and permeabilized cells (41) . Table III shows the results  of binding 125 I-JRF/A␤tot/17 to control L/APP cells as well as cells treated for 3 h with 10 M calpeptin or calpain inhibitor III. Treatment with either inhibitor resulted in a small increase in the number of JRF/A␤tot/17 binding sites in permeabilized cells (ϳ1.2-fold with both treatments), consistent with the slight increase in APP levels seen by Western blot analysis following calpain inhibition (Fig. 2) . JRF/A␤tot/17 binding at the cell surface increased ϳ1.6-fold with inhibitor treatment, with the JRF/A␤tot/17 binding at the cell surface as a percentage of total binding increasing from 8.6 to ϳ11%. Thus, inhibiting calpains results in a partial redistribution of APP (and possibly ␤CTFs, since JRF/A␤tot/17 recognizes both species), so that the steady-state levels in the plasma membrane are increased. In an additional experiment, we did a similar analysis of surface versus total JRF/A␤tot/17 binding sites at multiple time points following the addition of 10 M calpeptin (data not shown). We found that the increase in JRF/A␤tot/17 binding at the cell surface was extremely rapid (1.8-fold increase after 15-min treatment compared with a maximal 2.3-fold after 6 h). As previously seen, JRF/A␤tot/17 binding to permeabilized cells increased as well (remaining at 1.2-fold from 1.5 to 6 h), although the kinetics were somewhat slower than the increase in surface JRF/A␤tot/17 binding sites.
To determine the effect of calpain inhibition on ␤CTF levels and its cell surface distribution, we performed a similar quantitative 125 I-JRF/A␤N/25 binding experiment (Table IV) . Calpeptin and calpain inhibitor III increased the binding of JRF/A␤N/25 to permeabilized cells by 2-and 2.5-fold, respectively, confirming the dramatic increase in the levels of this APP metabolite following calpain inhibition. Calpain inhibition also dramatically increased JRF/A␤N/25 binding at the cell surface (nearly 5-fold). As a percentage of total JRF/A␤N/25 binding, cell surface binding increased 2.8-fold with calpeptin treatment and 1.6-fold with calpain inhibitor III treatment. The roughly proportionate increase in total (average of 2.3-fold for both inhibitors) and cell surface (average 2.2-fold) JRF/A␤N/25 binding suggests that ␤CTFs are in equilibrium between the intracellular pool and the plasma membrane population following calpain inhibition.
Taken together, these 125 I-mAb binding findings and the immunolabeling patterns seen in Figs. 5 and 6 indicate greater levels of APP holoprotein in the plasma membrane following calpain inhibition. Importantly, JRF/A␤tot/17 does not detect the ␣CTF, an important APP species seen with calpain inhibition (see Figs. 3 and 4) and an APP metabolite thought to be generated at the cell surface (7, 55) . Therefore, the increase in JRF/A␤tot/17 binding to intact cells following calpain inhibition is likely to substantially underestimate the total pool of APP cell-associated metabolites (APP holoprotein, ␣CTF, and ␤CTF) found at the cell surface.
DISCUSSION
Our results confirm previous reports that calpain inhibition increases the secretion of A␤42 relative to A␤40 (36, 37, 39) ; in fact, we find that treating cells with calpain inhibitors increases A␤42 production far beyond the increase due to the expression of FAD mutant PS1 in the same cell (Fig. 2) and beyond that generally reported by others following mutant PS1 expression in either cell culture or transgenic mice (16 -18) . A number of lines FIG. 5 . sAPP␣ and sAPP␤ production increases following calpain inhibition. L/APP cells were metabolically labeled for 15 min and chased for the indicated times. sAPP␣ and sAPP␤ were isolated from the chase media by sequential immunoprecipitation using 6E10 to first capture sAPP␣ followed by P2-1 (48) immunoprecipitation to isolate the remaining sAPP␤ (42) . Cells were treated with 10 M calpeptin as described in the legend to Fig. 3 . of evidence suggest that this effect results specifically from a reduction of calpain activity within the cell. In addition to the two inhibitors used in this study (calpeptin and calpain inhibitor III), others have shown similar effects using these and other calpainselective peptidyl aldehyde protease inhibitors (38, 39) . While many of these inhibitors can also inhibit the proteasome at high concentrations, Yamazaki et al. (36) demonstrated that the proteosome-selective inhibitor lactacystin did not increase A␤42 secretion selectively, as did calpain-selective inhibitors. Additionally, in this study it was shown that cells treated with an inhibitory domain of calpastatin showed an increase in A␤42 secretion relative to A␤40, arguing for a direct role of calpain activity in this effect. Similarly, we have transiently overexpressed a single inhibitory domain of calpastatin in L/APP4 cells and seen increased APP immunolabeling at the cell surface in transfected cells. 2 The manipulation of calpain activity in a cell by calpastatin overexpression is likely to be the best mechanism 2 S. D. Schmidt and P. M. Mathews, unpublished data. to directly implicate calpain activity in APP trafficking and metabolism and is something we are currently pursuing. Inhibiting Calpains Redistributes APP to the Cell Surface, Resulting in an Increase in ␣-and ␤-Cleavage-The distribution of APP between the TGN and the cell surface is highly regulated. Phosphorylation of APP by protein kinase C, for example, results in a redistribution of the protein to the plasma membrane, increasing ␣-cleavage while reducing A␤ generation (56, 57) . Multiple lines of evidence suggest that much ␣-cleavage occurs at the cell surface, including shedding of cell surface iodinated APP as sAPP␣ (7), the localization of the proteolytically active form of ADAM 10 to the plasma membrane (5) , and the significant reduction of ␣-cleavage by a cell-impermeant metalloproteinase inhibitor in a human neuroblastoma cell line (6) . The picture may be more complex, however, since Lee and colleagues have proposed that the protein kinase C-regulated increase in ␣-cleavage occurs within the TGN, in contrast to constitutive ␣-cleavage, which occurs at the cell surface (58) . Given that we detect a greater proportion of APP at the cell surface following calpain inhibition, the simplest explanation for the increase in ␣-cleavage seen in these cells would be the increased availability of APP for cell surface TACE and/or ADAM 10.
Moreover, the increase in both ␣-and ␤-cleavage is likely to be due to a rapid equilibrium between APP at the cell surface, where ␣-cleavage is likely to occur, and APP within early endosomes, where growing evidence points toward this compartment as being a major ␤-cleavage site. The evidence that cell surface APP is likely to be in rapid communication with early endosomes is substantial (59) and includes the findings that removal (14) or replacement (12) of the cytoplasmic tail of APP results in more APP at the cell surface by preventing its internalization. Koo and collaborators (13) have gone further by mapping discrete internalization motifs within this domain. Interestingly, those mutations that prevent or reduce the endocytosis of APP also reduce A␤ generation, one line of evidence that endosomes are critical sites for either ␤-or ␥-cleavage. Most reports have now placed BACE within early endosomes and/or throughout the endosomal-lysosomal system (9 -11), although some disagreement remains as to other intracellular compartments where this protease might be located (60) . Coupled with our data showing ␤CTFs within early endosomes (Fig. 5) , this strongly suggests that early endosomes are a major, if not the major, site for ␤-cleavage of APP.
Our findings support a model in which the intracellular distribution of APP is altered by calpain inhibition. Our data directly support increased levels of APP at the cell surface following calpain inhibition, and rapid communication between the plasma membrane and early endosome is likely (14) . Were these two compartments in equilibrium, such an increase in APP levels would result in a similar increase in both ␣-cleavage at the cell surface and ␤-cleavage within early endosomes, as we found by metabolic labeling and immunoprecipitation. This redistribution of APP toward the plasma membrane/early endosome from the TGN could result from either of two, not mutually exclusive, mechanisms: 1) APP egress from the TGN is increased and/or 2) recycling of APP from the cell surface/ early endosome to the TGN is inhibited. Such a TGN recycling pathway plays a critical role in maintaining the distribution of some proteins that are primarily found within the TGN but also at the cell surface (e.g. furin (61) and TGN38 (62)). Additional experimentation will be required to determine whether the TGN recycling pathway contributes to the subcellular distribution of APP. Nevertheless, if this were the case, it would raise the possibility that other metabolites of APP, such as the ␤CTF, may also recycle, permitting APP fragments generated in early endosomes to return to the Golgi apparatus, perhaps to undergo further proteolytic processing (e.g. ␥-cleavage).
Relationship of Calpain Inhibition and ␥-42-Secretase Activity-Whereas the changes in the intracellular distribution of APP following calpain inhibition appear to lead to increased ␤CTF production and then to drive A␤42 generation, we do not yet know why these additional ␤CTFs are substrates primarily for ␥-42-secretase activity. One possibility is that inhibiting calpains has a direct impact on the ␥-secretase activity of a cell, favoring ␥-42-secretase activity over ␥-40-secretase activity. The available evidence suggests that this is, at best, only a partial explanation of the calpain inhibition effect. We and others (36, 37, 39) have shown that A␤40 production remains the same or is slightly increased following calpain inhibition, suggesting that calpain inhibition does not prevent ␥-40-secretase activity, thereby driving all ␥-cleavage toward a ␥-42-secretase pathway. Additionally, we were unable to saturate A␤42 production with increasing concentrations of calpain inhibitors in either control or mutant PS1-expressing L cells. Whereas these experiments are limited by the toxicity of these inhibitors at the highest concentration, the increase in A␤42 appeared to closely parallel the increase in CTFs. This suggests two distinct mechanisms by which A␤42 production can be increased: by modified activity of the presenilin complex independent of an increase in ␤CTFs (e.g. mutant PS (16 -18) ) or in a ␤CTF-dependent fashion following calpain inhibition. Interestingly, an interaction between the large cytoplasmic loop domain of PS2 and -calpain has been reported, suggesting that calpains may directly regulate PS function (63), potentially linking calpain activity with ␥-secretase function. A second possibility is that the subcellular compartment in which ␥-cleavage occurs can play a critical role in determining whether A␤40 or A␤42 is generated (64) . Some experiments have shown early endosomes to have the capacity to generate A␤42 (13) , with others suggesting that compartments within the secretory pathway may (65) or may not (66) generate A␤42. If calpain inhibition affects the intracellular trafficking of the ␤CTF as well as APP, it may well be that the ␤CTFs are directed to a compartment(s) within the cell that is primarily ␥42-cleavage-competent.
Relationship between the Calpain System and Neurodegeneration-Generally, increased calpain activity is thought to play a role in the development of pathological cytoskeletal changes (32) (33) (34) (35) or to place a neuron at greater risk following an additional insult. At higher levels of activation, calpains may directly precipitate cell death, particularly in ischemia and excitotoxicity (28, 29) . If reduced calpain activity were to promote AD pathology by increasing A␤ generation, particularly A␤42, this would contrast with increased calpain activity promoting pathological tau changes. It may be that during the extended time course of AD in humans, the calpain system plays multiple roles, initially promoting A␤ generation and, later in the disease, responding to and exacerbating tau pathology. Both a greater understanding of the role of the calpain system in APP metabolism and a better assessment of endogenous calpain activity in neurons (67) will be necessary to dissect the relationship between either decreased or increased calpain activity and developing pathology. Nevertheless, as our understanding of the complex relationships between calpain activity and the regulation of seemingly disparate cellular events grows, the probability that calpains are intimately involved in the disease process appears likely. Finally, this study and previous studies (36, 37, 39) should raise concern as calpain inhibitors are aggressively pursued for their neuroprotective effects. Chronically inhibiting calpain activity and, there-fore, inducing a dramatic increase in A␤42 generation may have negative consequences.
